Evidence-Based Complementary and Alternative Medicine

Research Article

The Efficacy and Safety of Mesalamine and Probiotics in Mild-to-Moderate Ulcerative Colitis: A Systematic Review and Meta-Analysis

Table 1

General characteristics of included studies.


Author, Publication year	Study design	Study location	Sex (M/F)	Age (year) (mean ± SD) (or range)	The course of disease (mean ± SD) (or range)	Sample size	The dosage of treatment		Treatment period (week)	Outcome
Author, Publication year	Study design	Study location	Sex (M/F)	Age (year) (mean ± SD) (or range)	The course of disease (mean ± SD) (or range)	Sample size	T	C	Treatment period (week)	Outcome

Wang 2018 [28]	RCT	China	T: 32/31 C: 33/30	T: 32.49 ± 3.76 C: 32.61 ± 4.04	T: 16.75 ± 4.46 m C: 16.94 ± 4.68 m	126	Mesalamine 0.5 g, TID + Bifid Triple Viable Capsules 3 capsules, BID	Mesalamine 0.5 g, TID	4	①⑤
Wang et al. 2013 [29]	RCT	China	T: 19/14 C: 19/11	—	T: 0.5∼5.5y C: 0.5∼6y	63	Mesalamine 1.5 g, TID + Bifid Triple Viable Capsules 2 capsules, TID	Mesalamine 1.5 g, TID	8	①⑤
Chen et al. 2019 [30]	RCT	China	T: 25/25 C: 28/22	T: 69.26 ± 9.30 C: 69.11 ± 9.14	T: 3.41 ± 2.37y C: 3.63 ± 2.50y	100	Mesalamine 1.0 g, QID + Bifidobacterium triplex 0.42 g, TID	Mesalamine 1.0 g, QID	8	①
Luo 2008 [31]	RCT	China	T: 25/14 C: 19/9	T: 19∼59 C: 21∼69	T: 0.5∼13y C: 0.5∼11y	67	Mesalamine 0.5∼1.0 g, TID + Bifid Triple Viable Capsules 0.42 g, TID	Mesalamine 0.5∼1.0 g, TID	8	⑤
Wang 2013 [32]	RCT	China	—	T: 20∼75 C: 17∼72	T: 0.5∼5.5y C: 0.5∼6y	70	Mesalamine 1.0 g, QID + combined Bifidobacterium and Lactobacillus 2 g, TID	Mesalamine 1.0 g, QID	4	①⑤
Zhang 2017 [33]	RCT	China	T: 15/10 C: 14/11	T: 42.3 ± 2.1 C: 44.9 ± 3.7	—	50	Mesalamine 1.0 g, QID + Bifidobacterium triplex 0.42 g, TID	Mesalamine 1.0 g, QID	8	①②③⑤
Wang 2016 [34]	RCT	China	T: 19/16 C: 21/14	T: 45.3 ± 9.7 C: 44.6 ± 9.4	T: 5.3 ± 1.5y C: 4.8 ± 1.2y	70	Mesalamine 1.0 g, TID + Lactobacillus 100 ml, TID	Mesalamine 1.0 g, TID	24	①
Xing et al. 2017 [19]	RCT	China	T: 29/26 C: 28/27	T: 34.0 ± 5.0 C: 33.4 ± 4.5	T: 4.5 ± 0.5y C: 4.0 ± 0.5y	110	Mesalamine 1.0 g, QID + Bifid Triple Viable Capsules, 2∼4 capsule, BID	Mesalamine 1.0 g, QID	8	①⑤
Liu et al. 2010 [35]	RCT	China	—	—	—	58	Mesalamine 1.0 g, QID + Bifid Triple Viable Capsules 0.42 g, TID	Mesalamine 1.0 g, QID	4	①⑤
Li et al. 2017 [36]	RCT	China	T: 14/12 C: 13/12	T: 43.2 ± 5.1 C: 42.6 ± 4.9	—	51	Mesalamine 1.0 g, QID + Bifidobacterium triplex 0.42 g, TID	Mesalamine 1.0 g, QID	8	①②③④⑤
Gao 2018 [37]	RCT	China	T: 33/25 C: 32/26	T: 35.26 ± 6.26 C: 35.67 ± 6.14	T: 5.52 ± 2.02y C: 5.74 ± 1.68y	116	Mesalamine 1.0 g, TID + Bifid Triple Viable Capsules 0.42 g, TID	Mesalamine 1.0 g, TID	12	①⑤
Cheng 2018 [38]	RCT	China	T: 22/21 C: 24/19	T: 39.5 ± 3.3 C: 38.4 ± 3.2	T: 3.6 ± 0.5y C: 3.5 ± 0.8y	86	Mesalamine 1.0 g, TID + Bifidobacterium quadruple viable tablet 0.2 g, TID	Mesalamine 1.0 g, TID	8	①⑤
Liu et al. 2013 [39]	RCT	China	T: 16/20 C: 14/22	T: 49.36 ± 2.62 C: 52.28 ± 2.53	—	72	Mesalamine 1.0 g, QID + Bifidobacterium triplex 0.42 g, TID	Mesalamine 1.0 g, QID	8	②③④⑤
Zhou 2019 [40]	RCT	China	T: 13/7 C: 9/5	T: 19∼56 C: 21∼61	T: 0.5∼5y C: 0.5∼12y	34	Mesalamine 1.0 g, TID + Bifidobacterium triplex 0.42 g, TID	Mesalamine 1.0 g, TID	8	①⑤
Huang et al. 2018 [41]	RCT	China	T: 90/90 C: 81/99	T: 42.2 ± 9.4 C: 41.5 ± 8.3	T: 5.5 ± 1.8y C: 5.2 ± 1.7y	360	Mesalamine 1.0 g, TID + Bifid Triple Viable Capsules 0.42 g, TID	Mesalamine 1.0 g, TID	8	①③

Note. —: not mentioned; ①: clinical efficacy; ②: the clinical symptom scores; ③: disease activity index (DAI); ④: endoscopic score; and ⑤: adverse events.